Measure 1.3

The project will involve R&D activities, followed by the implementation into production of a biphasic biomaterial for the regeneration of osteochondral defects, under Measure 1.3 Research and Innovation in the Enterprise Sector, Priority I Research and Innovation, of the European Funds for Lubelskie 2021–2027 programme.

Within the scope of the project, industrial research will be conducted, encompassing the optimization of the quantity and type of components used in the production of the biomaterial, the development of an optimal manufacturing process, as well as the selection of appropriate packaging and sterilization methods. Consequently, specific components exhibiting the most optimal properties will be selected, and a prototype of the biomaterial for testing will be developed. The project also entails experimental development consisting of the manufacturing and sterilization of the biomaterial for animal implantation purposes, and the necessary studies to assess biological safety for implantation in laboratory animals, followed by—upon obtaining positive results and approvals—implantation in animal patients at veterinary clinics. The final project activities will focus on the implementation of R&D results, including the purchase of fixed assets necessary for the production of the biomaterial, and obtaining trademark and industrial design protection for the biomaterial.

The ultimate end-users of the project’s results, in the form of the biomaterial, will be the owners of the animals implanted with the new biomaterial, while the potential customers for the biomaterial will be veterinary clinics, hospitals, and practices.

The primary outcome of the project’s implementation will be the development of a new, innovative product under the working name “OsteoChondral Graft”. This will result in faster recovery times for animals due to a reduced risk of complications and inflammation. Furthermore, the project will contribute to reducing surgical time thanks to the ease of adapting the implant to the defect. The project constitutes an essential step towards the future certification of the product as a medical device for human use.